The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease - Kidney International
OncoPrescribe - Write The Perfect Prescription
Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance - Journal of Lipid Research
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Pa | TCRM
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer | Request PDF
The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease - Kidney International
Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer - Cancer Treatment Reviews
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations | Future Oncology
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer | HTML
Taselisib - an overview | ScienceDirect Topics
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations | Future Oncology
A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations | Endocrinology
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Eme | BCTT
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report | Clinical Diabetes and Endocrinology | Full Text
Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2–Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations - Clinical Breast Cancer
The mechanistic basis of PI3K inhibitor-associated hyperglycemia [5,... | Download Scientific Diagram
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications | Breast Cancer Research | Full Text
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | Nature Cancer
The PI3K signaling pathway and inhibitors under development and/or... | Download Scientific Diagram
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer | HTML
Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors - Ando - 2019 - Cancer Science - Wiley Online Library
Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer | Nature Reviews Endocrinology
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer | HTML
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients - Cancer Treatment Reviews
